-- 1 of 20 -- st April 16, 2024 -- 2 of 20 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc; and Kenvue’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 20 -- REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications Immunology INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Neuroscience PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Infectious Diseases INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Cardiovascular/ Metabolism/Other IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Oncology UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Pulmonary Hypertension Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre- clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Global Public Health Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 20 -- John Reed Executive Vice President, Innovative Medicine, R&D Enterprise highlights Sales performance and earnings review Capital allocation and guidance Q&A Agenda 1 2 3 4 5 Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, Medtech -- 5 of 20 -- Jessica Moore Vice President, Investor Relations -- 6 of 20 -- % Change Q1 2023 Q1 2024 Regional sales results1 Operational2 ex COVID-19 Vaccine Operational2 Reported 7.8% 7.8% 7.8% $10.8 $11.6 U.S. 6.0 (7.7) (7.6) 5.6 5.2 Europe 21.3 21.3 11.0 1.1 1.2 Western Hemisphere (ex U.S.) 5.0 5.0 (1.1) 3.4 3.4 Asia-Pacific, Africa 7.4 (0.3) (3.4) 10.1 9.8 International 7.6% 3.9% 2.3% $20.9 $21.4 Worldwide (WW) Dollars in billions 1 Results have been recast to reflect the continuing operations of Johnson & Johnson 2 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 1st Quarter 2024 sales 7 -- 7 of 20 -- $21.4 $20.9 $6.6 $6.3 12.4%; 12.8%2 $2.71 $2.41 Dollars in billions, except EPS Reported %; Operational %2 Sales Adjusted earnings3 Adjusted EPS3 2.3%; 3.9%2, 7.6%2,4 GAAP earnings / (loss) $5.4 ($0.5) 3.8% $2.20 ($0.19) Q1 2024 Q1 2023 * Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive 1 Results have been recast to reflect the continuing operations of Johnson & Johnson 2 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 4 Excluding COVID-19 Vaccine 1st Quarter 2024 financial highlights1 GAAP earnings / (loss) per share (diluted / basic*) 8 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 -- 8 of 20 -- Immunology $4,247 Infectious Diseases $821 Neuroscience $1,803 Oncology $4,814 CVM/Other $829 PH $1,049 ■ Reported growth ■ Operational growth1 $13,562 1.1%, 8.3%3 WW sales $MM Key drivers of operational performance1 • TREMFYA increase due to market growth and share gains • SIMPONI/SIMPONI ARIA increase driven by OUS growth • STELARA driven by market growth and share gains in IBD, partially offset by unfavorable patient mix • REMICADE decline due to biosimilar competition Immunology • COVID-19 Vaccine revenue decline Infectious Diseases • SPRAVATO growth driven by increased physician and patient demand • Growth partially offset by declines in RISPERDAL CONSTA Neuroscience • DARZALEX increase driven by continued strong share gains in all regions • ERLEADA increase driven by continued share gains and market growth • CARVYKTI increase driven by continued share gains, capacity expansion, and manufacturing efficiencies • TECVAYLI driven by ongoing launch • Growth in Other Oncology driven by launch of TALVEY and RYBREVANT • Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA decline due to global competitive pressure Oncology • XARELTO decline due to unfavorable patient mix and share loss Cardiovascular / Metabolism / Other (CVM/Other) • UPTRAVI and OPSUMIT growth driven by favorable patient mix, market growth, and share gains Pulmonary Hypertension (PH) Adjusted operational sales2,3: WW: 8.3%, U.S. 8.4%, Int’l 8.3% Innovative Medicine highlights – 1st quarter 2024 WW 1.1%, U.S. 8.4%, Int’l (6.9)% Reported: WW 8.3%, U.S. 8.4%, Int’l 8.3% Operational1,3: (10.6)%, (10.5)% 20.2%, 22.4% 17.1%, 18.8% (48.3)%, (48.3)%4 3.3%, 4.6% Strong adjusted operational growth1 of 8.3%3 driven by Oncology, PH, and Immunology 0.0%, 2.2% 9 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 Excluding COVID-19 Vaccine 4 Including COVID-19 Vaccine Note: Values may be rounded -- 9 of 20 -- Key drivers of operational performance1 • Electrophysiology: Double-digit increase driven by global procedure growth, new products (QDOT, OCTARAY), commercial execution, and Asia Pacific distributor inventory dynamics, partially offset by volume-based procurement (VBP) in China and fewer selling days • Abiomed: Strength from all major commercialized regions driven by continued strong adoption of Impella 5.5 and Impella RP Cardiovascular3 • Hips: Reflects global procedure growth, continued portfolio strength (primarily in the Anterior approach), and a one- time revenue recognition timing change related to certain products in the U.S., partially offset by Russia sanctions and one less selling day • Trauma: Growth driven by a one-time revenue recognition timing change related to certain products in the U.S., and continued adoption of recently launched products (Advanced Nailing Systems and Cannulated Compression Headless Screws), partially offset by U.S. competitive challenges, fewer selling days, weather-related softness in core trauma, and VBP • Knees: Growth driven by procedures, continued strength of the ATTUNE portfolio (Cementless & Medial Stabilized), pull through related to the VELYS Robotic assisted solution, a one-time revenue recognition timing change related to certain products in the U.S., and OUS tender timing, partially offset by one less selling day • Spine, Sports & Other: Reflects growth in Digital Solutions, Craniomaxillofacial, Shoulders, and a one-time revenue recognition timing change related to certain products in the U.S., partially offset by spine competitive pressures and one less selling day • Spine: ~ +1% WW, ~ +5% U.S., ~ -4% OUS Orthopaedics • Advanced: • Biosurgery: ~ +9% Increase driven by global procedures, strength of the portfolio (SURGIFLO, SURGICEL Powder, Evarrest, and VISTASEAL), and commercial execution • Endocutters: ~ -4% Primarily due to competitive pressures in the U.S., Bariatric procedure softness, China VBP and OUS inventory stocking dynamics and tender timing, partially offset by success of recently launched products (ECHELON 3000) • Energy: ~ -7% Driven by competitive pressures, VBP, and Harmonic market decline in the U.S., partially offset by uptake of new products OUS • General: Growth primarily due to procedures coupled with technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures), partially offset by fewer selling days Surgery • Contact Lenses/Other: Driven by U.S. stocking dynamics and economic pressures in Asia Pacific, partially offset by continued strong performance of the ACUVUE OASYS 1-Day family (including recent launch of OASYS MAX 1-day) and price actions • Surgical: Reflects continued strength of recent innovation (TECNIS EYHANCE & TECNIS EYHANCE Toric) and commercial execution, partially offset by inventory revaluation in China in preparation for VBP implementation and refractive softness in the U.S. Vision Adjusted operational sales2: WW 6.5%, U.S. 6.8%, Int’l 6.2% Orthopaedics $2,340 Surgery $2,416 Vision $1,258 Cardiovascular3 $1,806 ■ Reported growth ■ Operational growth1 $7,821 4.5%, 6.3% WW Sales $MM Solid operational growth1 due to procedures, strong commercial execution, and innovation WW 4.5%, U.S. 6.6%, Int’l 2.4% Reported: WW 6.3%, U.S. 6.6%, Int’l 6.1% Operational1: 20.2%, 22.5% (3.3)%, (1.4)% 4.3%, 4.8% (0.7)%, 1.9% MedTech highlights – 1st quarter 2024 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 Previously referred to as Interventional Solutions Note: Values may be rounded 10 -- 10 of 20 -- % Increase (Decrease) 2023 2024 % to Sales Amount % to Sales Amount 2.3 100.0 $20,894 100.0 $21,383 Sales to customers (2.6) 32.0 6,687 30.4 6,511 Cost of products sold 4.7 68.0 14,207 69.6 14,872 Gross Profit 7.2 23.5 4,906 24.6 5,257 Selling, marketing and administrative expenses 2.5 16.6 3,455 16.6 3,542 Research and development expense 0.2 49 - - In-process research and development impairments 0.1 14 (1.0) (209) Interest (income) expense, net 33.2 6,940 (1.5) (322) Other (income) expense, net 0.6 130 0.8 164 Restructuring (6.2) (1,287) 30.1 6,440 Earnings / (loss) before provision for taxes on income (3.9) (796) 5.1 1,086 Provision for / (Benefit from) taxes on income (2.3) ($491) 25.0 $5,354 Net Earnings / (loss) from Continuing Operations 423 - Net Earnings from Discontinued Operations, net of tax ($68) $5,354 Net Earnings / (loss) - ($0.19) $2.20 Net earnings / (loss) per share (Diluted/Basic) from Continuing Operations $0.16 - Net earnings per share (Diluted) from Discontinued Operations 2,605.5* 2,430.1 Average shares outstanding (Diluted/Basic) 61.8% 16.9% Effective tax rate from Continuing Operations . Adjusted earnings from Continuing Operations before provision for taxes and net earnings2 4.5 36.1 $7,536 36.8 $7,877 Earnings before provision for taxes on income from Continuing Operations 3.8 30.3 $6,340 30.8 $6,580 Net earnings from Continuing Operations 12.4 $2.41 $2.71 Net earnings per share (Diluted) from Continuing Operations 2,634.3 2,430.1 Average shares outstanding (Diluted) 15.9% 16.5% Effective tax rate from continuing operations * Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive 1 Results have been recast to reflect the continuing operations of Johnson & Johnson 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 1st Quarter 2024 (Unaudited; Dollar and shares in millions except per share figures) Condensed consolidated statement of earnings1 11 -- 11 of 20 -- Innovative Medicine MedTech Expenses not allocated to segments FY 2023 Q1 2023 Q1 2024 42.0% 42.9% 42.9% Innovative Medicine 23.7% 26.5% 26.4% MedTech 35.0% 36.1% 36.8% Total % to sales Adjusted income before tax by segment1,2 1 Results have been recast to reflect the continuing operations of Johnson & Johnson 2 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3 Estimated as of 4/16/2024 Note: Values may be rounded 1st Quarter 2024 $2.1 $2.0 $5.8 $5.8 2024 2023 $7.5B $7.9B ($0.2) 3 12 20243 -- 12 of 20 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 13 of 20 -- Innovative Medicine • Regulatory: – CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy2 – Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults – U.S. FDA Approves OPSYNVI (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH) – U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma – Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis – Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma – RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations – Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma – TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma – Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN) – Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma • Data release: – Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting2 – RYBREVANT (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer – New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year – Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine – Johnson & Johnson reports positive topline results for Nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD) – Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU MedTech • Regulatory: – Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation • Product launch: – Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform Enterprise – Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.242 – Johnson & Johnson to Acquire Shockwave Medical2 – Johnson & Johnson Completes Acquisition of Ambrx Notable announcements in 1st quarter 20241 1 These developments and all other news releases are available on the company’s website at News Releases as well as Innovative Medicine News Center, MedTech News & Events, www.factsabouttalc.com, and www.LLTManagementInformation.com 2 Subsequent to the quarter 14 -- 14 of 20 -- Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Q1 2024 Dollars in billions $26 Cash and marketable securities ($34) Debt ($7) Net debt ~$3. Free cash flow1,2 Q1 2024: $3.5B invested in R&D $2.9B in dividends paid to shareholders Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities less additions to property, plant and equipment 2 Estimated as of April 16, 2024. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 15 -- 15 of 20 -- Comments January 2024 April 2024 Tightening range; Increasing midpoint to 5.8% 5.0% - 6.0% 5.5% - 6.0% Adjusted operational sales2,3,7 Tightening range; Increasing midpoint to 5.8% $88.2B - $89.0B 5.0% - 6.0% $88.7B - $89.1B 5.5% - 6.0% Operational sales3,7 Midpoint of $88.2B or 5.0% Incremental FX ($0.3B) or (0.3%) $87.8B - $88.6B 4.5% - 5.5% $88.0B - $88.4B 4.7% - 5.2% Estimated reported sales 4,7 Maintain Improvement of ~50 bps Improvement of ~50 bps Adjusted pre-tax operating margin5,6 Maintain $1.2 - $1.4 billion $1.2 - $1.4 billion Net other income5 Increase based on Q1 actuals ($450) – ($550) million ($550) – ($650) million Net interest expense / (income) Maintain 16.0% - 17.0% 16.0% - 17.0% Effective tax rate5 Tightening of range; Increasing midpoint by $0.03 $10.55 - $10.75 6.4% - 8.4% $10.60 - $10.75 6.9% - 8.4% Adjusted EPS (operational)3,5 Tightening of range; Maintaining midpoint of $10.65 Incremental FX of ($0.03) $10.55 - $10.75 6.4% - 8.4% $10.57 - $10.72 6.6% - 8.1% Adjusted EPS (reported)4,5 2024 P&L guidance1 Tightening the range and increasing the midpoint of operational sales and adjusted operational EPS guidance (Guidance excludes impact from the recently announced acquisition of Shockwave Medical) 1 Results have been recast to reflect the continuing operations of Johnson & Johnson 5 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes acquisitions and divestitures 6 Sales less: COGS, SM&A and R&D expenses 3 Non-GAAP measure; excludes the impact of translational currency 7 Excludes COVID-19 Vaccine 4 Euro Average Rate: April 2024 = $1.08; Euro Spot Rate: April 2024 = $1.08 Note: Values may be rounded 16 -- 16 of 20 -- Innovative Medicine • Expect slightly stronger sales growth in the first half of the year compared to the second  Continued uptake from recently launched products  Anticipated entry of Stelara biosimilars in Europe towards the middle of the year • Operational sales growth expected to be relatively consistent throughout the year  2024 procedure volumes remain above pre-COVID levels  Modest impact from Russia sanctions in first half of the year  VBP pricing for Surgical IOLs and Sports in 2024; lapping of 2023 VBP impacts throughout the year Phasing Considerations MedTech EPS growth will benefit from 191MM share reduction in the first half of the year; partial benefit in Q3 P&L 17 -- 17 of 20 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, Medtech -- 18 of 20 -- Slide footer goes here if required 19 -- 19 of 20 -- = Achieved POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum of Check Change Sum of Check Change Sum of Check Change Phase III OPSUMIT (macitentan) US OPSUMIT (macitentan) US SIMPONI (golimumab) TREMFYA (guselkumab) EU Pediatric Pulmonary Arterial Hypertension (TOMORROW) Pediatric Pulmonary Arterial Hypertension (TOMORROW) EU Pediatric Ulcerative Colitis Crohn's Disease (GALAXI) P US OPSYNVI (macitentan/tadalafil STCT) UPTRAVI (selexipag) STELARA (ustekinumab) TREMFYA (guselkumab) EU Pulmonary Arterial Hypertension EU Pediatric Pulmonary Arterial Hypertension (SALTO) EU Pediatric Crohn's Disease Ulcerative Colitis Monotherapy (QUASAR) P US EDURANT (rilpivirine) US nipocalimab US TREMFYA (guselkumab) RYBREVANT (amivantamab) EU HIV pediatric 2-12 year old EU Generalized Myasthenia Gravis Pediatric Psoriasis Subcutaneous (PALOMA-3) P US^ BALVERSA (erdafitinib) US RYBREVANT (amivantamab) US TREMFYA (guselkumab) ERLEADA (apalutamide) EU Urothelial Cancer (THOR) EU Subcutaneous (PALOMA-3) EU Crohn's Disease (GALAXI) High Risk Prostate Cancer (PROTEUS) US DARZALEX (daratumumab) P US DARZALEX (daratumumab) US TREMFYA (guselkumab) seltorexant Frontline multiple myeloma transplant eligible (PERSEUS) P EU Frontline multiple myeloma transplant eligible (PERSEUS) Pediatric Juvenile Psoriatic Arthritis Adjunctive treatment for major depressive disorder with insomnia symptoms P US CARVYKTI (ciltacabtagene autoleucel) REKAMBYS P US TREMFYA (guselkumab) nipocalimab EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) EU HIV Adolescents EU Ulcerative Colitis Monotherapy (QUASAR) Generalized Myasthenia Gravis P US RYBREVANT (amivantamab) US TREMFYA (guselkumab) TREMFYA (guselkumab) EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Ulcerative Colitis Subcutaneous Induction (ASTRO) Crohn's Disease Subcutaneous Induction (GRAVITI) US RYBREVANT / lazertinib US TREMFYA (guselkumab) aticaprant EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) EU Crohn's Disease Subcutaneous Induction (GRAVITI) Adjunctive Major Depressive Disorder US RYBREVANT / lazertinib SPRAVATO (esketamine) monotherapy EU Non Small Cell Lung Cancer (MARIPOSA) Treatment Resistant Depression (TRD4005) Phase II Combination Therapy Psoriatic Arthritis nipocalimab Sjogren's Disease TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024* *This information is as of April 16, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval -- 20 of 20 --